SCHEMBL10134619

SCHEMBL10134619

COC(=O)c1ccc2[nH]c(=O)c3ccncc3c2c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.81
CSNK2A1 P68400 3/20 0.81
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
KIF11 P52732 2/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
CSNK2A2 P19784 1/20 0.47
CSNK2B P67870 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
DYRK1A Q13627 1/20 0.45
CREBBP Q92793 1/20 0.45
ROCK2 O75116 2/20 0.45
ROCK1 Q13464 1/20 0.45
ACHE P22303 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30704691 0.90 PARP1 (1.00) PARP1CSNK2A1KDM4EALDH1A1HPGD
SCHEMBL629270 0.90 PARP1 (1.00) PARP1CSNK2A1KDM4EALDH1A1HPGD
SCHEMBL2691509 0.85 PARP1 (0.90) PARP1CSNK2A1KDM4EALDH1A1HPGD
SCHEMBL10134618 0.82 PARP1 (0.70) PARP1CSNK2A1KDM4EALDH1A1DYRK1A
SCHEMBL30824328 0.81 PARP1 (0.64) PARP1CSNK2A1KDM4EALDH1A1HPGD
SCHEMBL28063129 0.79 KIF11 (0.70) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30172793 0.77 PARP1 (0.74) PARP1CSNK2A1KIF11RAB9ACSNK2A2
SCHEMBL13780270 0.76 KDM4E (0.62) PARP1CSNK2A1KDM4EALDH1A1HPGD
SCHEMBL30052472 0.76 KDM4E (0.52) PARP1CSNK2A1KDM4EALDH1A1HPGD
SCHEMBL16377295 0.76 PARP1 (0.76) PARP1CSNK2A1KIF11RAB9ACSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A1 680/4885KDM4E 736/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PARP1 690/4885CSNK2A1 680/4885KDM4E 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.